semaglutide blood brain barrier GLP-1 and the Degenerating Brain: Exploring Mechanistic Insights and Therapeutic Potential GLP-1 Drugs and the Physiology

In cellular experiments, data are expressed as means SD

doi: 10.3389/fphys.2026.1764165 Received 15 January 2026 Revised 29 December 2025 Accepted 19 January 2026 Published 09 February 2026 Volume 17 - 2026 Edited by Khosrow Kashfi, City University of New York, United States Reviewed by Jerzy Beltowski, Medical University of Lublin, Poland John Toscano, Johns Hopkins University, United States Updates Copyright 2026 Hirabayashi, Sasaki, Ohno, Takayama, Yamada and Hanaoka

To view a copy of this license, visit About this article Cite this article Tan, M., Yin, Y., Ma, X

Injectable use is off-label and not reimbursable

10.1161/CIRCRESAHA.120.315865 21 MarsoS

Liraglutide and Semaglutide Market Restrain Various side effects associated with liraglutide and semaglutide use for diabetes and obesity treatment may significantly hamper the market growth